MIV-210

MP4

www.hbvhbv.com/forum/thread-264814-1-21.html

www.medivir.se/v3/en/RnD/projects/lagociclovir.cfm

Therapy Area An NRTI for treatment of  hepatitis B (HBV) and HIV patients. Competitive Edge Against both multiresistant HBV and HIV that has become multiresistant to other drugs on the market. Very potent effect in hepatitis model in vivo. Excellent pharmacokinetic properties in phase I and effect against multiresistant HIV in pilot study. Licensee Hainan Noken has licensed MIV-210 for the Chinese market and is developing MIV-210 as a potential treatment against hepatitis B.

Last Modified: 12/05/2009

闹心啊

又是核苷类药物，这么多年了好像二三期实验还没进行
。疗效比拉米好不够，估计很难赶上替诺和恩替，市场机会不大。上市很难。

interdetect

回复 MP4 的帖子

Medivir集团的英国子公司Medivir AB于12月27日宣布，葛兰素史克公司（GlaxoSmithKline，GSK）已经终止了与其共同开发抗HIV药物MIV-210的合作协议，因为本品没有达到GSK的预期目标。在对来自Medivir和GSK两公司的本品临床前研究资料进行分析的基础上，Medivir公司决定继续开发本品，并且将本品的目标患者群集中于已有治疗......